Chi Michael Buys 13,650 HIMS Shares at $5.01/Share on July 23, 2025.
PorAinvest
viernes, 25 de julio de 2025, 10:54 pm ET1 min de lectura
HIMS--
These transactions come at a critical time for Hims & Hers Health. The company reported a significant 110.7% increase in revenue year-over-year, with earnings per share (EPS) hitting $0.20, surpassing analyst expectations [1]. Despite this positive financial performance, the stock has faced volatility, with a recent 0.3% increase to $57.50 following a 34.6% drop on June 23, 2025, when Novo Nordisk announced the termination of its partnership with Hims & Hers Health [2].
Analyst ratings for HIMS have been mixed, with a consensus rating of "Hold" and a consensus target price of $39.83 [1]. Several institutional investors have recently increased their stakes in the company, with Webster Bank N.A. and Parallel Advisors LLC among those adding to their holdings [1].
Investors should closely monitor these developments, as insider trading can often provide insights into a company's future prospects. However, it is essential to consider the broader context, including the company's financial performance and market conditions, when making investment decisions.
References:
[1] https://www.marketbeat.com/instant-alerts/michael-chi-sells-2100-shares-of-hims-hers-health-inc-nysehims-stock-2025-07-25/
[2] https://www.marketscreener.com/news/hims-hers-health-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-ce7c5fdbdf8ef021
NVO--
Hims & Hers Health, Inc. (HIMS) has announced that Chi Michael, the company's Chief Commercial Officer, made several transactions on July 23 and July 24, 2025. Specifically, Michael purchased 12,600 shares at $5.01 per share on July 23, as well as 900 shares at $6.82 per share on the same day. Additionally, he acquired 250 shares at $11.53 per share on July 23. On July 24, Michael sold 13,750 shares at $56 per share, and also purchased 2,100 shares at $5.01 per share, which he subsequently sold at $57.52 per share.
Hims & Hers Health, Inc. (HIMS) has seen a flurry of insider trading activity recently, with Chief Commercial Officer Michael Chi engaging in several transactions on July 23 and July 24, 2025. On July 23, Chi purchased 12,600 shares at $5.01 per share, 900 shares at $6.82 per share, and 250 shares at $11.53 per share. On July 24, he sold 13,750 shares at $56 per share and subsequently purchased 2,100 shares at $5.01 per share, which he sold at $57.52 per share [1].These transactions come at a critical time for Hims & Hers Health. The company reported a significant 110.7% increase in revenue year-over-year, with earnings per share (EPS) hitting $0.20, surpassing analyst expectations [1]. Despite this positive financial performance, the stock has faced volatility, with a recent 0.3% increase to $57.50 following a 34.6% drop on June 23, 2025, when Novo Nordisk announced the termination of its partnership with Hims & Hers Health [2].
Analyst ratings for HIMS have been mixed, with a consensus rating of "Hold" and a consensus target price of $39.83 [1]. Several institutional investors have recently increased their stakes in the company, with Webster Bank N.A. and Parallel Advisors LLC among those adding to their holdings [1].
Investors should closely monitor these developments, as insider trading can often provide insights into a company's future prospects. However, it is essential to consider the broader context, including the company's financial performance and market conditions, when making investment decisions.
References:
[1] https://www.marketbeat.com/instant-alerts/michael-chi-sells-2100-shares-of-hims-hers-health-inc-nysehims-stock-2025-07-25/
[2] https://www.marketscreener.com/news/hims-hers-health-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-ce7c5fdbdf8ef021
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios